




Mandated Use of State Prescription Drug Monitoring Programs (PMPs) – State Map

Research Current Through December 31, 2016.

This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government.

© 2016 National Alliance for Model State Drug Laws (NAMSDL) and Sherry L. Green & Associates, LLC (SLGA). Research is current as of December 31, 2016. Research is conducted using both nationwide legal database software and individual state legislative/regulatory websites. This document may be reproduced in whole or in part for non-commercial purposes with full attribution to NAMSDL and SLGA. Please contact Sherry Green at sgreen@namsdl.org or at 505.692.0457 with any additional updates or information that may be relevant to this map. For more information about NAMSDL, please go to www.namsdl.org

Mandated Use of PMPs – 35 States with Specified Circumstances Requiring Access



Some or all of the state's mandates are effective in 2017. State's mandate effective in 2018. Physicians must consider reviewing the PMP for the treatment of pain. Mandate effective six months after certification that PMP ready for statewide use and DOJ has adequate staff, user support, and education. For specific specific circumstances in which a state's prescribers and/or dispensers have to access PMP data, see the compilation entitled *Mandated Use of State Prescription Drug Monitoring Programs (PMPs) – Specified Circumstances Requiring Prescribers/Dispensers to Access PMP Data*.